140 related articles for article (PubMed ID: 17293073)
1. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring.
von Falck C; Maecker B; Schirg E; Boerner AR; Knapp WH; Klein C; Galanski M
Eur J Radiol; 2007 Sep; 63(3):427-35. PubMed ID: 17293073
[TBL] [Abstract][Full Text] [Related]
2. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis.
Vali R; Punnett A; Bajno L; Moineddin R; Shammas A
Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450
[TBL] [Abstract][Full Text] [Related]
3. (18)F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder.
Takehana CS; Twist CJ; Mosci C; Quon A; Mittra E; Iagaru A
Nucl Med Commun; 2014 Mar; 35(3):276-81. PubMed ID: 24296883
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography scanning in the setting of post-transplant lymphoproliferative disorders.
Blaes AH; Cioc AM; Froelich JW; Peterson BA; Dunitz JM
Clin Transplant; 2009; 23(6):794-9. PubMed ID: 20447185
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET/CT in abdominal post-transplant lymphoproliferative disease.
Metser U; Lo G
Br J Radiol; 2016; 89(1057):20150844. PubMed ID: 26544161
[TBL] [Abstract][Full Text] [Related]
6. Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease.
Bianchi E; Pascual M; Nicod M; Delaloye AB; Duchosal MA
Transplantation; 2008 Mar; 85(5):707-12. PubMed ID: 18337664
[TBL] [Abstract][Full Text] [Related]
7. The role of 18F-FDG PET/CT in the evaluation of pediatric transplant patients.
Yang J; Zhuang H
Hell J Nucl Med; 2015; 18(2):136-9. PubMed ID: 26187213
[TBL] [Abstract][Full Text] [Related]
8.
Montes de Jesus FM; Glaudemans AWJM; Tissing WJ; Dierckx RAJO; Rosati S; Diepstra A; Noordzij W; Kwee TC
J Nucl Med; 2020 Sep; 61(9):1307-1313. PubMed ID: 32005775
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experience on the use of PET/CT in the management of pediatric post-transplant lymphoproliferative disorder.
Guerra-García P; Hirsch S; Levine DS; Taj MM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612477
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients.
Marom EM; McAdams HP; Butnor KJ; Coleman RE
J Thorac Imaging; 2004 Apr; 19(2):74-8. PubMed ID: 15071322
[TBL] [Abstract][Full Text] [Related]
11. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.
Zimmermann H; Denecke T; Dreyling MH; Franzius C; Reinke P; Subklewe M; Amthauer H; Kneba M; Riess H; Trappe RU
Transplantation; 2018 May; 102(5):868-875. PubMed ID: 29189632
[TBL] [Abstract][Full Text] [Related]
12. FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation.
O'Conner AR; Franc BL
Nucl Med Commun; 2005 Dec; 26(12):1107-11. PubMed ID: 16264358
[TBL] [Abstract][Full Text] [Related]
13. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder.
Panagiotidis E; Quigley AM; Pencharz D; Ardeshna K; Syed R; Sajjan R; Bomanji J
Leuk Lymphoma; 2014 Mar; 55(3):515-9. PubMed ID: 23772644
[TBL] [Abstract][Full Text] [Related]
14. Roles of F-18-Fluoro-2-Deoxy-Glucose PET/Computed Tomography Scans in the Management of Post-Transplant Lymphoproliferative Disease in Pediatric Patient.
Xu YF; Yang JG
PET Clin; 2020 Jul; 15(3):309-319. PubMed ID: 32498987
[TBL] [Abstract][Full Text] [Related]
15. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.
Montes de Jesus FM; Kwee TC; Nijland M; Kahle XU; Huls G; Dierckx RAJO; van Meerten T; Gheysens O; Dierickx D; Vergote V; Noordzij W; Glaudemans AWJM
Crit Rev Oncol Hematol; 2018 Dec; 132():27-38. PubMed ID: 30447925
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic role of whole-body [18F]-FDG positron emission tomography in patients with symptoms suspicious for malignancy after heart transplantation.
Graute V; Jansen N; Sohn HY; Becker A; Klein B; Schmid I; Greil S; Lehner S; Bartenstein P; Pfluger T; Hacker M
J Heart Lung Transplant; 2012 Sep; 31(9):958-66. PubMed ID: 22766023
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield.
Montes de Jesus FM; Kwee TC; Kahle XU; Nijland M; van Meerten T; Huls G; Dierckx RAJO; Rosati S; Diepstra A; van der Bij W; Verschuuren EAM; Glaudemans AWJM; Noordzij W
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):529-536. PubMed ID: 31444510
[TBL] [Abstract][Full Text] [Related]
18. The value of
Si Z; Lu D; Zhai L; Zheng W; Dong C; Sun C; Wang K; Zhang W; Wei X; Zhang Z; Zhao S; Gao W; Shen Z
Pediatr Transplant; 2023 Aug; 27(5):e14501. PubMed ID: 36906739
[TBL] [Abstract][Full Text] [Related]
19. Detection of bone marrow involvement in newly diagnosed post-transplant lymphoproliferative disorder: (18)F-fluorodeoxyglucose positron emission tomography/computed tomography versus bone marrow biopsy.
Gheysens O; Thielemans S; Morscio J; Boeckx N; Goffin KE; Deroose CM; Sagaert X; Wlodarska I; Verhoef G; Dierickx D; Tousseyn T
Leuk Lymphoma; 2016 Oct; 57(10):2382-8. PubMed ID: 26854937
[TBL] [Abstract][Full Text] [Related]
20. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
Bakker NA; van Imhoff GW; Verschuuren EA; van Son WJ
Transpl Int; 2007 Mar; 20(3):207-18. PubMed ID: 17291214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
